Objectives: to compare the efficacy of retinoic acid 5% peeling with microdermabrasion and microdermabrasion with placebo for treatment of photoaging. Design: non randomized, single blind, clinical trial. Setting and conduct: in Alzahra hospital and Sedighe Tahere research center, eligible patients receive microdermabrasion on total face. This device abrade epiderm and superficial derm by aluminum oxide crystals and refer to Zagromed Company. Then the right side of face received retinoic acid 5% cream and the left side received placebo that was made by base of peeling cream. Treatment will be done in three sessions by one month interval. Outcome measures will be assessed by the use of serial photography at baseline, two weeks, one month, two months and four months after treatment, by two independent dermatologists. Inclusion criteria: informed consent for participation, no sensitivity to retinoic acid compounds, no treating for photoaging for at least three months before participation in study. Exclusion criteria: no using drug regularly, no referring regularly, discontinuing intervention, using other treatment modality within study. Intervention: right side of face receives microdermabrasion with retinoic acid 5% peeling and the left side receives microdermabrasion with placebo. Main outcome measures: improvement in photoaging assessed by two independent dermatologists by means of serial photography.